ASRS 2019 Street Team: Raj K. Maturi, MD

Article
Conference|ASRS

ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process

Raj K. Maturi, MD, discusses phase II data from the abicipar Phase II MAPLE Trial for patients with AMD at the 2019 annual ASRS conference.

Related Videos
Related Content
Image credit: ©NicoElNino– stock.adobe.com

RetinAI teams up with Stephen J. Ryan Initiative for Macular Research AMD Consortium

November 30th 2023
Article
Putting in practice retina innovations amid a pandemic

Putting in practice retina innovations amid a pandemic

August 28th 2020
Podcast
AAO 2023: Real-world outcomes for faricimab for AMD

AAO 2023: Real-world outcomes for faricimab for AMD

November 27th 2023
Article
EyePod

ASRS 2020: Evaluating 3-year-recurrence rate in non-infectious posterior segment uveitis post-FAi

July 29th 2020
Podcast
Image credit: ©Roman Motizov – stock.adobe.com

EyeBio announces expansion of Series A to $130 Million, advances development of Restoret for retinal diseases

November 22nd 2023
Article
Image credit: ©xavier gallego morel – stock.adobe.com

Leveling the playing field when comparing the efficacy of pegcetacoplan and avacincaptad pegol in patients with GA

November 16th 2023
Article
© 2023 MJH Life Sciences

All rights reserved.